Opinion on drug spending reduction due to biosimilars for specialty drugs 2017-2020

Percentage of U.S. health care executives who foresee biosimilars reducing drug spend for specialty drugs in 2017-2020*

Download
Show detailed source information?
Register for free
Already a member?
Log in
Sources

Use Ask Statista Research Service

Release date

May 2018

Region

United States

Survey time period

as of December 2015

Number of respondents

228 respondents

Special properties

executives involved in health care industry

Supplementary notes

* Executives at medical practices, hospitals, large healthcare systems, benefit management organizations, health plans, long-term care organizations, group purchasing organizations and consulting firms.

Citation formats
Statista Accounts: Access All Statistics. Starting from $2,388 USD / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account.

Starter Account
The ideal entry-level account for individual users
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references
$199 USD / Month *
Professional Account
Full access

Business Solutions including all features.

* Prices do not include sales tax.

Statistics on " Generics and biosimilars "

Other statistics that may interest you Generics and biosimilars

Global overview

4

Top companies

4

U.S. market

6

Patent expiration

6

Savings

7

Biosimilars

7

Further related statistics

17
Statista Accounts: Access All Statistics. Starting from $2,388 USD / Year
Learn more about how Statista can support your business.